i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
-
Published Date:
Oct 2009
-
Publisher's site:
-
Source:Emerg Infect Dis. 15(10):1556-1561.
-
Language:English
-
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:Patients receiving anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy are at increased risk for tuberculosis and other granulomatous diseases, but little is known about illness caused by nontuberculous mycobacteria (NTM) in this setting. We reviewed the US Food and Drug Administration MedWatch database for reports of NTM disease in patients receiving anti-TNF-alpha therapy. Of 239 reports collected, 105 (44%) met NTM disease criteria. Median age was 62 years; the majority of patients (66, 65%) were female, and most (73, 70%) had rheumatoid arthritis. NTM infections were associated with infliximab (n = 73), etanercept (n = 25), and adalimumab (n = 7); most patients were taking prednisone (n = 68, 65%) or methotrexate (n = 58, 55%) concurrently. Mycobacteria avium (n = 52, 50%) was most commonly implicated, and 9 patients (9%) had died at the time their infections were reported. A high rate of extrapulmonary manifestations (n = 46, 44%) was also reported.
-
Subject:
-
Pubmed ID:19861045
-
Pubmed Central ID:PMC2866401
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
image/gif image/jpeg image/gif image/jpeg text/plain text/plain
No Related Documents.